Shares

16 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2022

May 04, 2022

SELL
$14.08 - $27.63 $2.11 Million - $4.14 Million
-149,911 Closed
0 $0
Q4 2021

Feb 10, 2022

SELL
$26.55 - $40.57 $99,190 - $151,569
-3,736 Reduced 2.43%
149,911 $3.98 Million
Q3 2021

Nov 10, 2021

BUY
$39.27 - $72.94 $133,596 - $248,141
3,402 Added 2.26%
153,647 $6.31 Million
Q2 2021

Aug 13, 2021

SELL
$31.29 - $56.64 $2.63 Million - $4.75 Million
-83,916 Reduced 35.84%
150,245 $8.51 Million
Q1 2021

May 14, 2021

BUY
$39.71 - $90.58 $3.21 Million - $7.32 Million
80,810 Added 52.7%
234,161 $9.84 Million
Q4 2020

Feb 02, 2021

BUY
$27.07 - $84.35 $278,550 - $867,961
10,290 Added 7.19%
153,351 $10.8 Million
Q3 2020

Nov 05, 2020

BUY
$28.06 - $37.16 $546,019 - $723,096
19,459 Added 15.74%
143,061 $4.01 Million
Q2 2020

Aug 12, 2020

BUY
$18.5 - $34.34 $155,529 - $288,696
8,407 Added 7.3%
123,602 $3.66 Million
Q1 2020

May 12, 2020

SELL
$14.88 - $32.78 $14,880 - $32,780
-1,000 Reduced 0.86%
115,195 $2.28 Million
Q4 2019

Jan 27, 2020

BUY
$19.49 - $32.63 $446,223 - $747,063
22,895 Added 24.54%
116,195 $3.44 Million
Q3 2019

Oct 31, 2019

BUY
$22.49 - $26.81 $744,419 - $887,411
33,100 Added 54.98%
93,300 $2.12 Million
Q2 2019

Aug 15, 2019

SELL
$20.48 - $27.76 $22,528 - $30,536
-1,100 Reduced 1.79%
60,200 $1.49 Million
Q1 2019

May 03, 2019

SELL
$19.43 - $26.41 $190,064 - $258,342
-9,782 Reduced 13.76%
61,300 $1.5 Million
Q4 2018

Feb 08, 2019

BUY
$18.19 - $31.79 $487,492 - $851,972
26,800 Added 60.52%
71,082 $1.62 Million
Q3 2018

Nov 13, 2018

SELL
$27.65 - $38.39 $175,854 - $244,160
-6,360 Reduced 12.56%
44,282 $1.41 Million
Q2 2018

Aug 15, 2018

BUY
$31.4 - $41.01 $1.59 Million - $2.08 Million
50,642 New
50,642 $1.82 Million

Others Institutions Holding EDIT

About Editas Medicine, Inc.


  • Ticker EDIT
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 68,737,200
  • Market Cap $90M
  • Description
  • Editas Medicine, Inc., a clinical stage genome editing company, focuses on developing transformative genomic medicines to treat a range of serious diseases. It develops a proprietary gene editing platform based on CRISPR technology. The company develops EDIT-101, which is in Phase 1/2 clinical trial for Leber Congenital Amaurosis 10 that leads t...
More about EDIT
Track This Portfolio

Track California Public Employees Retirement System Portfolio

Follow California Public Employees Retirement System and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of California Public Employees Retirement System, based on Form 13F filings with the SEC.

News

Stay updated on California Public Employees Retirement System with notifications on news.